AUS
NZ
UK
CA
USA
IND
Healthcare
Why CLEO Diagnostics’ ASX Update Matters for Market Watchers
December 29, 2025 12:02 PM AEDT| By SamCLEO Diagnostics’ latest ASX update highlights how routine capital management aligns with transparency, liquidity, and short activity considerations across Australia’s diverse equity market.
Market Update: What CLEO’s New Share Quotation Signals for ASX Investors
December 29, 2025 11:55 AM AEDT| By SamCLEO Diagnostics’ quoted share expansion highlights disciplined capital management, reinforcing transparency and liquidity visibility within Australia’s healthcare innovation segment.
Memphasys CE Mark Approval Opens New European Pathways
December 29, 2025 11:45 AM AEDT| By SamMemphasys (ASX:MEM) steps forward with CE Mark approval for the Felix System, creating gateways to new markets and setting the foundation for broader global expansion.
CSL Limited Overview on ASX 300 With Market Context and Healthcare Developments
December 24, 2025 05:34 PM AEDT| By SamCSL Limited overview covering healthcare sector positioning, global operations, recent corporate context, and index inclusion within Australia’s equity market.
CSL’s Market Reset: What Its ASX 200 Journey Signals for Long-Term Investors
December 24, 2025 12:28 PM AEDT| By SamCSL’s recent market journey highlights shifting sentiment, resilient healthcare operations, and broader lessons about valuation and expectations within Australia’s leading equity indices.
Neurizon Therapeutics Strengthens ALS Trial Momentum
December 23, 2025 08:58 PM AEDT| By SamNeurizon Therapeutics strengthens its clinical development pathway through strategic funding, supporting ALS research progress within a global trial framework while reinforcing its position in the Australian healthcare market.
Actinogen’s ASX Move Signals a Fresh Chapter in Australian Biotech
December 23, 2025 04:48 PM AEDT| By SamActinogen Medical advances capital transparency through a new ASX quotation, reinforcing disciplined governance and supporting long-term innovation within Australia’s listed biotechnology sector.
Actinogen Medical Advances Market Access With New ASX Share Quotation
December 23, 2025 04:24 PM AEDT| By SamActinogen Medical’s ASX share quotation highlights how Australian listed companies manage capital structure updates within a transparent and regulated market environment.
Neurizon Therapeutics Advances ALS Research With New Capital
December 23, 2025 12:46 PM AEDT| By SamNeurizon Therapeutics advances its ALS clinical journey with new funding support, strengthening trial readiness and research momentum while remaining active within the ASX stock market ecosystem.
Dimerix Licensing Stability Signals Confidence After US Pharma Deal
December 22, 2025 12:55 PM AEDT| By SamThis article explores how Dimerix’s US licensing arrangement stays intact after a major pharmaceutical acquisition, outlining implications for drug development, global partnerships, and the broader ASX stock market landscape.
Illuccix Progress in China Strengthens Telix’s Global Pathway
December 22, 2025 12:35 PM AEDT| By SamTelix Pharmaceuticals advances its global imaging strategy as China study outcomes strengthen regulatory confidence and support broader adoption of precision diagnostics across key oncology markets.
Healthcare Equipment Focus as ResMed Appears in ASX 100 Landscape
December 19, 2025 06:14 PM AEDT| By SamResMed operates within the healthcare equipment sector, combining medical devices and digital platforms while maintaining visibility across major Australian indices.
Memphasys and the ASX 300 Setting in the Local Healthcare Space
December 19, 2025 06:09 PM AEDT| By SamMemphasys released a corporate update on additional share quotation, reflecting standard disclosure practices within the Australian healthcare sector and the ASX framework.
Prescient Therapeutics Advances Europe Trial Path for PTX
December 19, 2025 05:15 PM AEDT| By SamThis article explores how Prescient Therapeutics is expanding its European clinical program, strengthening global research efforts, and advancing PTX development through regulated trial pathways.
Ansell Limited’s Measured Approach to Debt and Stability
December 19, 2025 05:10 PM AEDT| By SamThis article explores how Ansell Limited manages debt responsibly, supported by cash flow discipline, balance sheet strength, and long-term business fundamentals within the Australian equity landscape.
Are SHL Shares at a Turning Point for Long-Term Watchers?
December 19, 2025 05:04 PM AEDT| By SamAn in-depth look at Sonic Healthcare and Xero, exploring business models, market positioning, and valuation perspectives shaping discussion across the Australian share market.
Fresh Capital Update Signals Strategic Momentum at 4DMedical
December 19, 2025 04:06 PM AEDT| By SamAn in-depth look at 4DMedical’s latest ASX share quotation move, exploring capital structure dynamics, sector context, and broader market relevance in a clear, investor-friendly format.
Amplia Expands Cancer Research With New Global Collaboration
December 19, 2025 12:27 PM AEDT| By SamAn in-depth look at Amplia Therapeutics’ expanded research collaboration, its cancer pipeline direction, and how advanced preclinical models are shaping future oncology studies.
Radiopharm Theranostics Responds to ASX Rule Compliance Review
December 18, 2025 03:05 PM AEDT| By SamRadiopharm Theranostics has addressed a listing rule oversight, outlining governance enhancements and external advisory support to strengthen compliance and align future capital activities with ASX requirements.
Orthocell Reaches Key US Commercial Milestone With Remplir Uptake
December 18, 2025 12:35 PM AEDT| By SamOrthocell has reached an early US commercial milestone for Remplir, signalling growing adoption momentum supported by surgeon engagement, hospital access progress, and a disciplined international expansion strategy.
Advertise your brand on Kalkine Media